Atlas Venture Life Science Advisors, LLC Q3 2024 Filing

Filed November 13, 2024

Portfolio Value

$1.1T

Holdings

14

Report Date

Q3 2024

Filing Type

13F-HR

All Holdings (14 positions)

#StockSharesValue% PortfolioType
1
DYNDyne Therapeutics, Inc.
8,020,136$288.1B26.71%
2
KYMRKymera Therapeutics, Inc.
4,896,462$231.7B21.48%
3
THRDThird Harmonic Bio, Inc.
10,907,859$147.8B13.70%
4
IRONDisc Medicine, Inc.
2,509,456$123.3B11.43%
5
QTTBQ32 Bio, Inc.
2,092,106$93.3B8.65%
6
DAWNDay One Biopharmaceuticals, Inc.
6,430,257$89.6B8.30%
7
KRROKorro Bio, Inc.
1,137,149$38.0B3.52%
8
GBIOGBXGeneration Bio, Co.
8,279,484$20.5B1.90%
9
VIGLVigil Neuroscience, Inc.
5,836,874$19.8B1.84%
10
TECXTectonic Therapeutics, Inc.
378,447$11.5B1.06%
11
Ikena Oncology, Inc.
5,018,178$8.7B0.80%
12
AVTEAerovate Therapeutics, Inc.
1,799,232$3.8B0.35%
13
DNTHDianthus Therapeutics, Inc.
76,979$2.1B0.20%
14
SPROSpero Therapeutics, Inc.
402,885$539.9M0.05%